Literature DB >> 17479522

PET and SPECT imaging in psychiatric disorders.

Robert B Zipursky1, Jeffrey H Meyer, N Paul Verhoeff.   

Abstract

OBJECTIVES: To review recent findings from positron emission tomography (PET) and single photon emission computed tomography (SPECT) studies that investigate the pathophysiology and treatment of schizophrenia, depression, and dementia.
METHODS: We carried out a review of the literature.
RESULTS: PET and SPECT studies have provided evidence of dopamine system dysregulation in patients with schizophrenia and variable loss of monoamines in patients with depression. Antipsychotic response has been demonstrated to be associated with blockade of dopamine D2 receptors, and antidepressant response has now been linked to blockade of serotonin transporter receptors. PET and SPECT have been extensively evaluated as diagnostic procedures for dementia. Substantial progress has been made in developing radioligands that bind to amyloid deposits in the brain, which should provide new opportunities for early diagnosis and treatment monitoring in Alzheimer's disease.
CONCLUSION: Advances in PET and SPECT imaging have provided new insights into the biology of major psychiatric disorders and their treatment. In the future, we can expect that these imaging techniques will become more central to the management of psychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17479522     DOI: 10.1177/070674370705200303

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  12 in total

Review 1.  Molecular imaging in patients with mood disorders: a review of PET findings.

Authors:  Qiaozhen Chen; Weibo Liu; Huichun Li; Hong Zhang; Mei Tian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

2.  Cerebral morphology and dopamine D2/D3 receptor distribution in humans: a combined [18F]fallypride and voxel-based morphometry study.

Authors:  Neil D Woodward; David H Zald; Zhaohua Ding; Patrizia Riccardi; M Sib Ansari; Ronald M Baldwin; Ronald L Cowan; Rui Li; Robert M Kessler
Journal:  Neuroimage       Date:  2009-02-05       Impact factor: 6.556

3.  Neurotransmission and bipolar disorder: a systematic family-based association study.

Authors:  Jiajun Shi; Judith A Badner; Eiji Hattori; James B Potash; Virginia L Willour; Francis J McMahon; Elliot S Gershon; Chunyu Liu
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-10-05       Impact factor: 3.568

4.  Visual discrimination among patients with depression and schizophrenia and healthy individuals using semiquantitative color-coded fast spin-echo T1-weighted magnetic resonance imaging.

Authors:  Makoto Sasaki; Eri Shibata; Kotaro Ohtsuka; Jin Endoh; Kohsuke Kudo; Shinsuke Narumi; Akio Sakai
Journal:  Neuroradiology       Date:  2009-09-15       Impact factor: 2.804

5.  Trace amine-associated receptor 1 as a monoaminergic modulator in brain.

Authors:  Zhihua Xie; Gregory M Miller
Journal:  Biochem Pharmacol       Date:  2009-05-29       Impact factor: 5.858

Review 6.  Advances in neuroimaging research of schizophrenia in China.

Authors:  Dengtang Liu; Yifeng Xu; Kaida Jiang
Journal:  Shanghai Arch Psychiatry       Date:  2014-08

Review 7.  Serotonin and mental disorders: a concise review on molecular neuroimaging evidence.

Authors:  Shih-Hsien Lin; Lan-Ting Lee; Yen Kuang Yang
Journal:  Clin Psychopharmacol Neurosci       Date:  2014-12-26       Impact factor: 2.582

8.  The association of DAT gene methylation with striatal DAT availability in healthy subjects.

Authors:  Kyoungjune Pak; Ju Won Seok; Hyun-Yeol Nam; Seongho Seo; Myung Jun Lee; Keunyoung Kim; In Joo Kim
Journal:  EJNMMI Res       Date:  2021-06-12       Impact factor: 3.138

Review 9.  Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?

Authors:  Brian M Ross; Jennifer Seguin; Lee E Sieswerda
Journal:  Lipids Health Dis       Date:  2007-09-18       Impact factor: 3.876

Review 10.  Cognitive Function and Monoamine Neurotransmission in Schizophrenia: Evidence From Positron Emission Tomography Studies.

Authors:  Harumasa Takano
Journal:  Front Psychiatry       Date:  2018-05-29       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.